Avalon GloboCare Receives Notice of Allowance for Groundbreaking CAR-T and CAR-NK Cell Technology in China

FREEHOLD, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, announced today that it has received a Notice of Allowance from the China National Intellectual Property Administration (CNIPA) for its patent application AVAR1901CN. This patent, co-developed with Hong Kong-based Arbele Limited, marks a milestone in the advancement of chimeric antigen receptor (CAR)-based therapies. It ...